Precision Medicine

A new report reveals payers are rewriting drug benefit rules, sacrificing rebates for more control as they grapple with the high cost of new therapies.

A new partnership brings a single-dose treatment for common, serious infections to Sub-Saharan Africa, a region with high prevalence and unmet medical needs.

A landmark study reveals essential phospholipids significantly reduce liver fat and fatigue in MASLD patients, offering a new tool against a silent epidemic.

By emphasizing deep anatomical knowledge, Medytox aims to elevate industry standards and solidify its leadership in Asia's booming medical aesthetics market.

Top expert Dr. Henrik Zetterberg joins Circular Genomics, signaling a pivotal shift toward novel circular RNA blood tests for neurodegenerative disease.

A revolutionary organ preservation system is showing 100% graft survival in new studies, promising to expand the donor pool for children in need.

Millions are using GLP-1 drugs for weight loss, but an unexpected side effect is emerging: a prominent 'buffalo hump' that surgery is now targeting.

A new study reveals that poor muscle quality, measured by advanced MRI, is a powerful predictor of death in CKD patients, shifting focus to systemic health.

Akumin unveils its renovated Plantation facility, blending advanced United Imaging tech with patient-centered design to set a new standard for diagnostics.

TGA approves Minjuvi, a dual-targeted immunotherapy for relapsed follicular lymphoma, offering a breakthrough option beyond traditional chemotherapy.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

An essay contest for medical trainees aims to fix a critical gap in patient care, using frontline stories to reshape how doctors learn about nutrition.

With a fresh CAD $1M in funding, Grey Matters is set to enter the booming U.S. neuroimaging market, targeting early Alzheimer's detection.

With the hire of world-renowned surgeon Dr. Nelson Oyesiku, Piedmont Healthcare signals its ambition to become a top destination for neurological care in the Southeast.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

A novel drug that targets the cellular environment of the MYC cancer protein, not the protein itself, shows major promise in preclinical studies.

Hyalex Orthopaedics’ new FDA-cleared Slalom™ implant, using cartilage-mimicking tech, offers a motion-preserving alternative to joint fusion.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.